There's likely a lot of hair on the AD results due to relatively small n, dosing complications, S1 status, and possibly other factors, and instead of transparency Missling went for selective disclosure in the TLR. Not the wise and credible course. But given our strong cash, negative effects on share price are irrelevant and leaves just the unnecessary delay and efficacy signal uncertainty. It has no bearing on partnerships or regulatory actions.
(The poor disclosure does raise some reputational risk given our ADL efficacy claim, but it's not that worrisome without the forthcoming full data.)